$SBFM .0147 +5.38% The global biopharmaceuticals m
Post# of 106881
(Total Views: 208)
Posted On: 12/10/2020 11:37:53 AM
$SBFM .0147 +5.38% The global biopharmaceuticals market accounted for USD 186,470 Million in 2017, and is projected to reach USD 526,008 Million by 2025 while registering a CAGR of 13.8% from 2018 to 2025, according to data provided be Allied Market Research.
Sunshine Biopharma Inc. (OTC: SBFM) announced yesterday breaking news that, "it has ordered a new batch of Adva-27a from its manufacturer in China. The material will be delivered to the laboratories of Sunshine Biopharma's drug development partner in Montreal (Canada). Sunshine plans to use the material to conduct testing on various types of cancer cells that overproduce Topoisomerase II (TopII). Following these cell culture studies, Sunshine will proceed to performing studies on mice harboring tumors of human origin with TopII amplification. TopII is an essential cell cycle enzyme that is amplified in approximately 4% of all human cancers.
'All cancer types that have amplification of the Topoisomerase II gene are potential new targets for our Adva-27a,' said Dr. Steve Slilaty, CEO of Sunshine Biopharma. 'This is an additional application for our Adva-27a beyond the original multidrug resistance indication,' he added.
About Sunshine Biopharma: In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a."
Sunshine Biopharma Inc. (OTC: SBFM), Onconova Therapeutics, Inc. (NASDAQ: ONTX), Ocugen, Inc. (NASDAQ: OCGN), Advaxis, Inc. (NASDAQ: ADXS), Moleculin Biotech, Inc. (NASDAQ: MBRX)
Sunshine Biopharma Inc. (OTC: SBFM) announced yesterday breaking news that, "it has ordered a new batch of Adva-27a from its manufacturer in China. The material will be delivered to the laboratories of Sunshine Biopharma's drug development partner in Montreal (Canada). Sunshine plans to use the material to conduct testing on various types of cancer cells that overproduce Topoisomerase II (TopII). Following these cell culture studies, Sunshine will proceed to performing studies on mice harboring tumors of human origin with TopII amplification. TopII is an essential cell cycle enzyme that is amplified in approximately 4% of all human cancers.
'All cancer types that have amplification of the Topoisomerase II gene are potential new targets for our Adva-27a,' said Dr. Steve Slilaty, CEO of Sunshine Biopharma. 'This is an additional application for our Adva-27a beyond the original multidrug resistance indication,' he added.
About Sunshine Biopharma: In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a."
Sunshine Biopharma Inc. (OTC: SBFM), Onconova Therapeutics, Inc. (NASDAQ: ONTX), Ocugen, Inc. (NASDAQ: OCGN), Advaxis, Inc. (NASDAQ: ADXS), Moleculin Biotech, Inc. (NASDAQ: MBRX)
(0)
(0)
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.